1. Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance
   Nidhi Goel et al, 2021, Molecular Cancer Therapeutics CrossRef
2. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
   Elizabeth H. Stover et al, 2019, Molecular Cancer Research CrossRef
3. Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell
   Gen Ba et al, 2020, Cell Cycle CrossRef
4. p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy
   Phong Lu et al, 2019, Molecular Pharmaceutics CrossRef
5. Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model
   Brittney S. Harrington et al, 2020, Cancers CrossRef
6. Germacrone Inhibits Cell Proliferation and Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cells
   Ren Zhang et al, 2020, BioMed Research International CrossRef
7. Mutagenic Consequences of Sublethal Cell Death Signaling
   Christine J. Hawkins et al, 2021, International Journal of Molecular Sciences CrossRef
8. Strategic Combination Therapies for Ovarian Cancer
   Xinran Li et al, 2020, Current Cancer Drug Targets CrossRef
9. The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers
   Khalid El Bairi et al, 2021, Ovarian Cancer Biomarkers CrossRef
10. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
    Ling Wang et al, 2020, Current Drug Targets CrossRef
11. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
    Goldie Y.L. Lui et al, 2020, EBioMedicine CrossRef
12. A Bayesian framework for pathway‐guided identification of cancer subgroups by integrating multiple types of genomic data
    Zequn Sun et al, 2023, Statistics in Medicine CrossRef
13. Identification of GNA12‑driven gene signatures and key signaling networks in ovarian cancer
    Ji-Hee Ha et al, 2021, Oncology Letters CrossRef
14. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
    Hubert Fleury et al, 2019, Nature Communications CrossRef
15. Bcl-2 family inhibitors sensitize human cancer models to therapy
    Elisabetta Valentini et al, 2023, Cell Death & Disease CrossRef
16. Mechanisms of Taxane Resistance
    Sara M. Maloney et al, 2020, Cancers CrossRef